CMS seeks public input on MU Stage 3 CQMs

The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on several new clinical quality measures (CQMs) for eligible professionals (EPs) that pertain to Meaningful Use (MU) Stage 3.

Mathematica Policy Research and its subcontractors, the National Committee for Quality Assurance and the Lewin Group, are developing CQMs for MU Stage 3. CMS is requesting that stakeholders review several measures and provide feedback on them. The proposed CQMs are

  • Overuse of diagnostic imaging for uncomplicated headaches
  • Appropriate use of dual-energy X-ray absorptiometry scans in women under 65 years who do not meet the risk factor profile

In these two areas, the CMS notice suggested feedback in the following areas:

  • Measures’ relevance to the mission of public reporting under the EHR Incentive Program component for EPs
  • Usefulness of the measures to improve quality of care for patients
  • Feasibility of data collection via EHRs for public reporting

CMS also is seeking feedback on the retooling of the influenza immunization as an eCQM to be derived from EHR data. Abt Associates, in collaboration with the Oklahoma Foundation for Medical Quality, are the measure developers leading the retooling of the influenza immunization measure.

According to CMS, comments pertaining to the following areas are desired: representation of the legacy measure constructs in the logic; value sets; and implementation considerations.

Comments are due by Nov. 25. For more information, go here.

 

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.